Advertisement

Advertisement

Gynecologic Cancers

Image-Guided IMRT Reduces GI Toxicity Without Compromising Pelvic Recurrence in Intermediate- to High-Risk Cervical Cancer

Post-hysterectomy image-guided intensity-modulated radiation therapy (IMRT) was superior to three-dimensional conformal radiation therapy (3D-CRT) in reducing the side effects of pelvic radiation while achieving similar tumor control in women with high-risk cervical cancer, according to the final...

Gynecologic Cancers
Immunotherapy

Pembrolizumab Plus Bevacizumab and Oral Metronomic Cyclophosphamide for Recurrent Ovarian Cancer

In a single-institution phase II trial reported in JAMA Oncology, Zsiros et al found that the combination of pembrolizumab with bevacizumab and oral metronomic cyclophosphamide produced objective response in approximately half of women with recurrent ovarian cancer taking part in the study....

Breast Cancer
Gynecologic Cancers
Genomics/Genetics

Screening Younger Women for Variants Linked to Breast and Ovarian Cancers May Be Cost-Effective

Population-wide screening for genetic variants linked to hereditary breast and ovarian cancers may be cost-effective in women between the ages of 20 and 35, according to a study published by Guzauskas et al in JAMA Network Open. However, screening for older women was not cost-effective, the...

Gynecologic Cancers

Sentinel Lymph Node Biopsy vs Lymphadenectomy for Staging of Intermediate- and High-Grade Endometrial Cancers

In a Canadian prospective cohort study (SENTOR) reported in JAMA Surgery, Cusimano et al found that sentinel lymph node biopsy showed “acceptable diagnostic accuracy” compared with lymphadenectomy in detecting nodal metastatic disease in patients with intermediate- and high-grade endometrial...

Breast Cancer
Lung Cancer
Gynecologic Cancers

FDA Approves Companion Diagnostic for Three Targeted Therapies for Advanced Ovarian, Breast, and Non–Small Cell Lung Cancers

On October 27, 2020, the U.S. Food and Drug Administration (FDA) approved the FoundationOne Liquid CDx test for three new companion diagnostic indications to help match patients who may benefit from treatment with specific FDA-approved targeted therapies. The new indications are for alpelisib...

Gynecologic Cancers

Expert Point of View: Andreas du Bois, MD, PhD

The invited discussant of the phase III INOVATYON trial was Andreas du Bois, MD, PhD, Chairman of the Department of Gynecology and Gynecologic Oncology at Kliniken Essen Mitte, Germany, and Chairman of the AGO Study Group. As Dr. du Bois explained, the study “dealt with an old question: Does...

Gynecologic Cancers

INOVATYON: Platinum-Based Regimens Remain Standard of Care in Recurrent Platinum-Sensitive Ovarian Cancer

Yet another blow has been dealt for the alkylating agent trabectedin in advanced ovarian cancer. The international phase III INOVATYON study found no improvement in overall or progression-free survival for trabectedin plus pegylated liposomal doxorubicin (PEG-LD) vs carboplatin/PEG-LD in patients...

Gynecologic Cancers
Immunotherapy

Expert Point of View: Ana Oaknin, MD, PhD

The innovaTV 204 trial’s invited discussant, Ana Oaknin, MD, PhD, Head of the Gynecologic Cancer Program at Vall d’Hebron Institute of Oncology in Barcelona, was encouraged by the study’s findings. “Of note, the response rate was 24%, the time to response was short, and the median duration of...

Gynecologic Cancers
Immunotherapy

Novel Treatments Show Activity in Advanced Cervical Cancer

The treatment of recurrent or metastatic cervical cancer has not changed much in recent years, but according to preliminary trials presented at the European Society for Medical Oncology (ESMO) Virtual Congress 2020, checkpoint inhibitors and antibody-drug conjugates may become new options. In the...

Gynecologic Cancers

Prediagnosis and Postdiagnosis Physical Activity and Survival in Endometrial Cancer

In a Canadian study reported in the Journal of Clinical Oncology, Friedenreich et al found that postdiagnosis recreational physical activity was associated with significantly improved disease-free and overall survival among women with invasive endometrial cancer. Study Details The prospective...

Gynecologic Cancers

SOLO-1 Trial: After 5 Years, Maintenance Olaparib Still Keeps Ovarian Cancer at Bay

The long-term results of the pivotal SOLO-1 trial have shown that maintenance olaparib more than doubles the 5-year disease-free survival time for patients who have newly diagnosed advanced ovarian cancer with BRCA mutations, according to an update presented at the European Society for Medical...

Breast Cancer
Gynecologic Cancers
Prostate Cancer
Genomics/Genetics

FDA Approves Companion Diagnostic for Three Targeted Therapies for Advanced Ovarian, Breast, and Non–Small Cell Lung Cancers

On October 27, the U.S. Food and Drug Administration (FDA) approved the FoundationOne Liquid CDx test for three new companion diagnostic indications to help match patients who may benefit from treatment with specific FDA-approved targeted therapies. The new indications are for alpelisib (Piqray) in ...

Gynecologic Cancers

The Gut, Our Choices, and Gynecologic Cancers: Investigating an Unlikely Trio

Disturbance of the gut microbial metabolism is thought to be the root cause of human diseases. Bacteria, viruses, and fungi affect their human hosts in numerous ways. There is evidence to support the theory that microbes, through their genetic makeup, gene products, and metabolites, play a role in...

Gynecologic Cancers
Immunotherapy

Addition of Bevacizumab to Paclitaxel in Relapsed Ovarian Sex Cord–Stromal Tumors

In the phase II ALIENOR trial reported in JAMA Oncology, Isabelle Ray-Coquard, MD, and colleagues found that the addition of bevacizumab to paclitaxel did not improve the 6-month progression-free rate among women with relapsed ovarian sex cord–stromal tumors. Study Details The study, performed in...

Gynecologic Cancers
Immunotherapy

Camrelizumab Plus Apatinib in Previously Treated Patients With Advanced Cervical Cancer

In the Chinese phase II CLAP study reported in the Journal of Clinical Oncology, Lan et al found that the combination of the anti–PD-1 antibody camrelizumab and the VEGFR inhibitor apatinib produced high response rates in previously treated women with advanced cervical cancer. Study Details The...

Gynecologic Cancers

Swedish Study of HPV Vaccination and Risk of Invasive Cervical Cancer

In a study reported in The New England Journal of Medicine, Lei et al found that receipt of the quadrivalent human papillomavirus (HPV) vaccine among girls and young women was associated with a substantial reduction in the risk of invasive cervical cancer. As stated by the investigators, “The...

Issues in Oncology
Gynecologic Cancers
Colorectal Cancer
COVID-19

A Primary Care Physician Explores Barriers to Cancer Prevention and Clinical Trial Accrual

To accelerate progress in the survival rates of people with cancer in the United States and to reduce cancer disparities across the entire spectrum of cancer from diagnosis to survivorship, there needs to be increased access to cancer screening and prevention programs. To shed light on this...

gynecologic cancers

Andreas du Bois, MD, PhD, on Ovarian Cancer: Niraparib, Trabectedin Plus Doxorubicin, Platinum, and Carboplatin

Andreas du Bois, MD, PhD, of Kliniken Essen Mitte, discusses the NORA and INOVATYON studies of patients with recurrent ovarian cancer, detailing the findings for women in China with platinum-sensitive disease and women internationally who received trabectedin and pegylated liposomal doxorubicin (PLD) followed by platinum at disease progression vs carboplatin and PLD after disease progression (Abstract LBA29 and LBA30).

Gynecologic Cancers

Early Cancer Experience Plants the Seed for a Career in Oncology to Grow for Joyce F. Liu, MD, MPH

As a young girl growing up in central New Jersey, Joyce F. Liu, MD, MPH, a medical oncologist specializing in gynecologic cancers at Dana-Farber Cancer Institute, Boston, dreamed of becoming an astronaut. However, she realized her fear of heights and propensity for motion sickness didn’t jive with...

Gynecologic Cancers

Does Radical Hysterectomy Improve Survival in Patients With Cervical Cancer and Intraoperative Detection of Positive Lymph Nodes?

No significant difference was observed in the risk of recurrence, local recurrence, or death between patients with cervical cancer in whom a radical uterine procedure (mostly radical hysterectomy) was completed or abandoned upon intraoperative detection of positive pelvic lymph nodes. These...

Gynecologic Cancers

SOLO1 5-Year Follow-up: Maintenance Olaparib for BRCA-Mutated Advanced Ovarian Cancer

Almost half of patients who received the PARP inhibitor olaparib for newly diagnosed BRCA-mutated advanced ovarian cancer remained disease-free after 5 years, according to data presented by Susana Banerjee, MBBS, PhD, and colleagues during the ESMO Virtual Congress 2020 (Abstract 811MO). Patients...

Gynecologic Cancers

World Gynecologic Oncology Awareness Day (World GO Day): September 20

Patient advocates and medical professionals in more than 20 countries have come together for the second annual World Gynecologic Oncology Day (World GO Day), taking place today, September 20. A project of the European Society of Gynaecological Oncology (ESGO) and the European Network of...

gynecologic cancers

Mansoor Raza Mirza, MD, on Endometrial Cancer: Palbociclib Plus Letrozole in ER-Positive Disease

Mansoor Raza Mirza, MD, of Copenhagen University Hospital, discusses phase II study results that showed the combination of palbociclib and letrozole, compared with placebo plus letrozole, improved progression-free survival in patients with estrogen receptor–positive advanced or recurrent endometrial cancer (Abstract LBA28).

Gynecologic Cancers

Addition of ATR Inhibitor Berzosertib to Gemcitabine Improves Progression-Free Survival in Recurrent Platinum-Resistant High-Grade Serous Ovarian Cancer

As reported in The Lancet Oncology by Panagiotis A. Konstantinopoulos, MD, Dana-Farber Cancer Institute, and colleagues, a U.S. Experimental Therapeutics Clinical Trials Network phase II trial has shown significantly prolonged progression-free survival with the addition of the ATR (ataxia...

Global Cancer Care
Gynecologic Cancers

Simple Rapid Vinegar Screening Test Cuts Cervical Cancer Death Rates by One-Third in Rural India

In 2013, at the ASCO Annual Meeting Plenary Session, it was both surprising and encouraging in the era of personalized medicine for cancer care to hear about a simple low-tech intervention delivered by women in the community that cut the rate of death from cervical cancer in India by about...

Gynecologic Cancers

Quality-Adjusted Progression-Free Survival and Time Without Symptoms or Toxicity in the ARIEL3 Trial of Rucaparib Maintenance Therapy for Recurrent Ovarian Cancer

In an exploratory post hoc analysis reported in the Journal of Clinical Oncology, Amit M. Oza, MD, and colleagues found superior quality-adjusted progression-free survival (QA-PFS) and quality-adjusted time without symptoms or toxicity (Q-TWiST) in patients with platinum-sensitive, recurrent...

Gynecologic Cancers
Immunotherapy

Expert Point of View: TROPHIMMUN Trial

Two gynecologic oncologists and ASCO’s Chief Medical Officer and Executive Vice President Richard L. Schilsky, MD, FACP, FSCT, FASCO, commented on the findings of the TROPHIMMUN trial for The ASCO Post. “The authors demonstrate efficacy of a new treatment approach for gestational trophoblastic...

Gynecologic Cancers
Immunotherapy

TROPHIMMUN Trial Finds Avelumab Effective in Rare Gynecologic Tumor Resistant to Chemotherapy

The first trial of immunotherapy for gestational trophoblastic tumors proved effective in almost 50% of patients resistant to single-agent chemotherapy, French investigators reported in an abstract presented during the ASCO20 Virtual Scientific Program.1 The results of the phase II TROPHIMMUN trial ...

Gynecologic Cancers

American Cancer Society Updates Guideline for Cervical Cancer Screening

An updated cervical cancer screening guideline from the American Cancer Society has called for less—and more simplified—screening. The guideline was published by Elizabeth T.H. Fontham, MPH, DrPH, of Louisiana State University School of Public Health, New Orleans, and colleagues in CA: A Cancer...

Gynecologic Cancers

Higher Risk of Disease Recurrence and Death With Minimally Invasive vs Open Surgery for Early-Stage Cervical Cancer

Women with early-stage cervical cancer treated with minimally invasive radical hysterectomy had a 71% increased risk of recurrence and a 56% increased risk of death compared with those treated with open radical hysterectomy, according to a systematic review and meta-analysis of 15 studies involving ...

Gynecologic Cancers
Immunotherapy

Lenvatinib/Pembrolizumab in Previously Treated Patients With Advanced Endometrial Cancer

As reported in the Journal of Clinical Oncology by Vicky Makker, MD, of Memorial Sloan Kettering Cancer Center, New York, and colleagues, findings from a phase Ib/II trial indicate that the combination of lenvatinib and pembrolizumab is active in patients with previously treated advanced...

Gynecologic Cancers
Immunotherapy

Addition of Trastuzumab to Carboplatin/Paclitaxel for Advanced or Recurrent HER2-Positive Uterine Serous Carcinoma

Combining the HER2-targeted therapy trastuzumab with carboplatin and paclitaxel improved survival rates for women with a rare, aggressive type of endometrial cancer, according to findings published by Amanda N. Fader, MD, of Johns Hopkins School of Medicine, Baltimore, and colleagues in Clinical...

Gynecologic Cancers

LACC Trial: Quality of Life With Open vs Minimally Invasive Radical Hysterectomy for Patients With Cervical Cancer

As reported in The Lancet Oncology by Michael Frumovitz, MD, of The University of Texas MD Anderson Cancer Center, Houston, and colleagues, there were no significant differences in quality of life, a secondary endpoint, for women undergoing open vs minimally invasive radical hysterectomy for...

Gynecologic Cancers
Genomics/Genetics

PORTEC-3: Effect of Molecular Classification of Endometrial Cancer on Outcomes With Adjuvant Therapy

In a study reported in the Journal of Clinical Oncology, Alicia Léon-Castillo, MD, of Leiden University Medical Center, the Netherlands, and colleagues identified outcomes associated with molecular subgroups of patients with high-risk endometrial cancer enrolled in the PORTEC-3 trial of adjuvant...

Gynecologic Cancers
COVID-19

Gynecologic Oncologist Describes Practice in the Era of COVID-19

The ASCO Post spoke with Alexander Melamed, MD, MPH, a gynecologic oncologist and Assistant Professor of Obstetrics & Gynecology at NewYork-Presbyterian/Columbia University Medical Center, New York, at the onset of the COVID-19 pandemic in New York. New York state has had more coronavirus cases ...

Gynecologic Cancers

Expert Point of View: Shannon N. Westin, MD, MPH, FACOG

Discussant of the abstract on the WEE1 inhibitor adavosertib, Shannon N. Westin, MD, MPH, FACOG, Associate Professor and clinical investigator at The University of Texas MD Anderson Cancer Center, called the interaction between p53 and WEE1 an “opportunity for synthetic lethality.” She continued:...

Gynecologic Cancers

SGO 2020: WEE1 Inhibitor Shows Activity in Recurrent Uterine Serous Carcinoma

Monotherapy with the experimental WEE1 inhibitor adavosertib has shown activity in patients with advanced recurrent or metastatic uterine serous carcinoma,1 according to data presented during the 2020 Society of Gynecologic Oncology (SGO) Annual Meeting on Women’s Cancer Webinar Series. The initial ...

Gynecologic Cancers
Immunotherapy

Expert Point of View: Nicoletta Colombo, MD

The invited discussant of the two trials in cervical and endometrial cancers presented at the ESMO Congress 2019 was Nicoletta ­Colombo, MD, of the University of Milan-Bicocca in Italy, who commented on what she called “exciting results in cancers with unmet needs.” Dr. Colombo noted: “The studies...

Gynecologic Cancers
Immunotherapy

ESMO 2019: Immunotherapy in Cervical and Endometrial Cancers

In studies reported at the ESMO Congress 2019, immunotherapy yielded encouraging outcomes in two gynecologic cancer populations in need of new treatments, including patients with advanced cervical cancer that is microsatellite-stable and patients previously treated for advanced endometrial cancer....

Gynecologic Cancers

SGO 2020: Updated Analysis of VELIA Trial Shows Antitumor Activity in Ovarian Cancer, but Is It Enough?

An updated analysis of the phase III VELIA/GOG-3005 trial, presented during the 2020 Society of Gynecologic Oncology (SGO) Annual Meeting on Women’s Cancer Webinar Series,1 suggested synergy between the poly (ADP-ribose) polymerase (PARP) inhibitor veliparib and platinum chemotherapy in the...

Gynecologic Cancers

ASCO20: Cediranib Plus Olaparib vs Standard-of-Care Chemotherapy for Platinum-Sensitive Ovarian Cancer

Results of the NRG Oncology phase III clinical trial NRG-GY004 indicated that the addition of the investigational agent cediranib to olaparib and standard platinum-based chemotherapy did not improve progression-free survival outcomes for women with platinum-sensitive ovarian cancer; however,...

Gynecologic Cancers

Effect of Statins on Survival in Ovarian Cancer

Lipophilic statin use was associated with reduced mortality in women with epithelial ovarian cancer and all subtypes in a large observational study compared with never users. These findings were presented at the 2020 American Association for Cancer Research (AACR) Virtual Annual Meeting II. Lead...

Gynecologic Cancers
Immunotherapy

KEYNOTE-100: In Women With Advanced Ovarian Cancer, Pembrolizumab Yields Modest Antitumor Efficacy

the final results of the phase II KEYNOTE-100 study of pembrolizumab in women with advanced and recurrent ovarian cancer showed that pembrolizumab monotherapy produced modest clinical activity. Ursula Matulonis, MD, of Dana-Farber Cancer Institute, Harvard Medical School, reported the data at the...

Gynecologic Cancers

ASCO20: Final Overall Survival Analysis From SOLO2 in Ovarian Cancer

For the first time, overall survival has been improved with maintenance therapy involving a poly (ADP-ribose) polymerase (PARP) inhibitor in patients with platinum-sensitive recurrent ovarian cancer associated with BRCA1/2 mutations. In the final, preplanned, overall survival analysis in the...

Gynecologic Cancers

Expert Point of View: Robert L. Coleman, MD

Discussant of the DESKTOP III and SOC1 trials, Robert L. Coleman, MD, of U.S. Oncology Research in Woodlands, Texas, congratulated the authors of both trials. He put these results in perspective with the GOG-0213 study, which did not show a survival benefit for secondary surgery. “There are general ...

Gynecologic Cancers

ASCO20: Secondary Surgery May Extend Survival in Recurrent Ovarian Cancer

Two phase III trials provided support for secondary cytoreductive surgery in women with recurrent ovarian cancer, with the caveats that patient selection is key and the surgery should be performed at sites of excellence. The results of the DESKTOP III and SOC1 trials, both presented during the...

Gynecologic Cancers

ESMO 2019: Veliparib Plus First-Line Chemotherapy and as Maintenance Therapy in High-Grade Ovarian Cancer

In the phase III VELIA/GOG-3005 trial—reported at the European Society for Medical Oncology (ESMO) Congress 20191 and simultaneously published in The New England Journal of Medicine2—Robert L. Coleman, MD, of The University of Texas MD Anderson Cancer Center, Houston, and colleagues found that the ...

Gynecologic Cancers

ESMO 2019: PRIMA Trial Reports Benefit With Niraparib Across Ovarian Cancer Subsets

In women with advanced ovarian cancer responding to first-line chemotherapy, maintenance therapy with the poly (ADP-ribose) polymerase (PARP) inhibitor niraparib significantly reduced the risk of disease progression by 38% overall and by 60% in women with BRCA mutations. Even patients without a...

Gynecologic Cancers

Novel Drug Approvals and New Indications for Gynecologic Cancers

A number of new drugs and novel indications were added to the treatment armamentarium for gynecologic cancers over the past year. The U.S. Food and Drug Administration (FDA) approvals are noted here. Olaparib, PARP Inhibitor On May 8, 2020, the FDA expanded the indication of olaparib (Lynparza) to...

Gynecologic Cancers

SGO 2020: Updated Data From PRIMA Trial: Niraparib as First-Line Maintenance Therapy for Advanced Ovarian Cancer

Making sense of maintenance therapy in advanced ovarian cancer has been a tall order since the publication of impressive data for not one but three poly (ADP-ribose) polymerase (PARP) inhibitors at the European Society for Medical Oncology (ESMO) 2019 Congress.1 The picture became a little clearer...

Advertisement

Advertisement

Advertisement